Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-22), Piramal Pharma's 3-1 Month Momentum % is 31.42%.
The industry rank for Piramal Pharma's 3-1 Month Momentum % or its related term are showing as below:
NSE:PPLPHARMA's 3-1 Month Momentum % is ranked better than 91.45% of 1018
companies
in the Drug Manufacturers industry
Industry Median: 2.325
vs NSE:PPLPHARMA: 31.42
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Piramal Pharma 3-1 Month Momentum % Related Terms
NSE:PPLPHARMA vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Piramal Pharma (NSE:PPLPHARMA) has a 3-1 Month Momentum % of 31.42% as of Sep. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Piramal Pharma and its competitors. According to the industry distribution chart, Piramal Pharma ranks #87 out of 1018 companies in the Drug Manufacturers industry, placing it in the top 8.5%.
Is Piramal Pharma's 3-1 Month Momentum % too high?
Piramal Pharma's current 3-1 Month Momentum % is 31.42%. The Drug Manufacturers industry median 3-1 Month Momentum % is 2.33. Piramal Pharma's value of 31.42% is 1251.4% above this industry median. Based on the distribution chart, Piramal Pharma ranks #87 out of 1018 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Piramal Pharma has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #87 out of 1018 companies for 3-1 Month Momentum %. This places Piramal Pharma in the top 9% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 2.33. Piramal Pharma's value of 31.42% is 1251.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 2.33, based on 1,018 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current 3-1 Month Momentum % of 31.42% is 1251.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current 3-1 Month Momentum % is 31.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹190.02, compared to a current price of ₹214.66 — trading 13% above its estimated fair value. The current 3-1 Month Momentum % is 31.42% and 1251.4% above the Drug Manufacturers industry median of 2.33. Piramal Pharma's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current 3-1 Month Momentum % is 31.42% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹214.66 is trading 13% above its estimated GF Value™ of ₹190.02.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
3-1 Month Momentum %: 31.42%
GF Value™: ₹190.02 vs. price of ₹214.66 (13% above fair value)
Industry Position: 1251.4% above the Drug Manufacturers median (#87 of 1018)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
52GF Score
Get the complete analysis for NSE:PPLPHARMA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
